

> ACUTE LEUKEMIA


# LEUKEMIA

ACUTE LEUKEMIA

定義

• Clonal proliferation of hematopoietic progenitor with failed differentiation into mature elements → ↑ blasts in bone marrow and periphery → ↓ RBCs, platelets, and neutrophils

流行病學 and risk factors

• Acute myelogenous (AML): ~20k cases/y in U.S.; median age 68 y

• Acute lymphocytic (ALL): ~6k cases/y in U.S.; median age 15 y but 2nd peak in older adults

• Risk factors: **radiation**, **chemo** (alkylating agents, topo II inhib), benzene, smoking, ? rising from acquired somatic mutations and clonal hematopoiesis (_NEJM_ 2014;371:2477)

• Secondary to acquired hematopoietic dis.: MDS, MPN (esp. CML), aplastic anemia, PNH

• Inherited: Down’s, Klinefelter’s, Fanconi’s anemia, Bloom syndrome, ataxia telangiectasia, Li-Fraumeni, germline mutations in _RUNX1_, _CEBPa_, & _GATA2_

臨床表現

• Cytopenias → **fatigue** (anemia), **infection** (neutropenia), **bleeding** (thrombocytopenia)

• More common in **AML**

### Leukostasis (more often when blast count >50,000/µL): dyspnea, hypoxemia, headache, blurred vision, confusion,TIA/CVA, interstitial infiltrates

### DIC (esp. with APL); leukemic infiltration of skin, gingiva (esp. with monocytic subtypes); chloroma: extramedullary tumor of leukemic cells, virtually any location

• More common in **ALL**

bony/lumbar pain, LAN, hepatosplenomegaly (also in monocytic AML), SVC syndrome

CNS involvement (up to 10%): cranial neuropathies, N/V, headache

anterior mediastinal mass (esp. in T-cell); tumor lysis syndrome (qv)

Diagnostic evaluation (_Blood_ 2009;114:937)

• **Peripheral smear:** anemia, thrombocytopenia, variable WBC + circulating **blasts** (seen in >95%; ⊕ Auer Rods in AML), peripheral flow cytometry for blast origin (ALL vs. AML)

• **Bone marrow:** >20% blasts; mostly hypercellular; test for cytogenetics and flow cytometry

• Presence of certain **cytogenetic anomalies**, eg, t(15;17), t(8;21), inv(16) or t(16;16), are sufficient for dx of AML _regardless of the blast count_

• ✔ for tumor lysis syndrome (rapid cell turnover): ↑ UA, ↑ LDH, ↑ K, ↑ PO4, ↓ Ca

• Coagulation studies to 排除 DIC: PT, PTT, fibrinogen, D-dimer, haptoglobin, bilirubin

• LP (w/ **co-admin of intrathecal chemotherapy** to avoid seeding CSF with circulating blasts) for 病人 with ALL (CNS is sanctuary site) and for 病人 with AML with CNS sx

• TTE if prior cardiac history or before use of anthracyclines

• **HLA typing** of Pt, siblings > parents/children for potential allogeneic HSCT candidates

ACUTE MYELOGENOUS LEUKEMIA (AML; _LANCET_ 2018;392:593)

Classification (WHO; _Blood_ 2016;127:2391)

• Features used to confirm myeloid lineage and subclassify AML to guide 治療: morphology: **blasts**, ⊕ **granules**, ± **Auer rods** (eosinophilic needle-like inclusions)

• Immunophenotype: precursor: CD34, CD45, HLA-DR; myeloid: CD13, CD33, CD117; monocyte: CD11b, CD64, CD14, CD15

• Prognosis: _age_, prior _antecedent MPN/MDS_ and _genetics_ (cytogenetics + molecular mutation status) are key independent risk factors

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>ENL 2017 Genetic Risk Classification</b> <span>(</span><span><i>Blood</i></span> <span>20</span><span>1</span><span>7;</span><span>1</span><span>29:424)</span></p></td></tr><tr><td><p><b>Risk Category</b></p></td><td><p><b>Genetic Abnormality</b></p></td></tr><tr><td><p>Favorable</p></td><td><p>APL: t(15;17);</p><p>t(8;21): RUNX1-RUNX1T1; inv(16): CBFB-MYH1;</p><p>mutated <i>NPM1 without FLT3-ITD or with FLT3-ITD<sup>low</sup></i>;</p><p>biallelic mutation in <i>CEBPA</i></p></td></tr><tr><td><p>Intermediate</p></td><td><p>FLT3-ITD<sup>low</sup>; mutated NPM1 &amp; FLT3-ITD<sup>high</sup>;</p><p>t(9;11): MLL-MLLT3;</p><p>cytogenetic 異常 not classified as favorable or adverse, including normal karyotype without mutations in FLT3-ITD &amp; NPM1</p></td></tr><tr><td><p>Adverse</p></td><td><p>-5 or del(5q); -7; -17/abn(17p); complex or monosomal karyotype;</p><p>t(6;9): DEK-NUP214 ; t(9;22) BCR-ABL1; inv(3): GATA2-MECOM;</p><p>wildtype NPM1 &amp; FLT-ITD<sup>high</sup>;</p><p>mutated TP53, RUNX1, ASXL1</p></td></tr></tbody></table>

Upfront 治療

• **Induction chemo** “7+3”: 7 d cont. infusion cytarabine (Ara-C) + 3 d bolus anthracycline

• Ability to tolerate 7+3 regimen key determinant in subsequent Rx received (see below)

• Newer regimens if **_fit_** (generally age <75 y)

FLT3-ITD/TKD mutation: 7+3+midostaurin (early generation FLT3 inhib; _NEJM_ 2017;377:454)

Cord-binding factor ⊕ → t(8;21) or inv(16): 7+3 ± gemtuzumab ozogamicin (mAb+cytotoxin)

2° AML or with MDS-related changes: CPX-351 (liposomal Ara-C & daunorubicin)

Other: age <60 y: 7+3 (high-dose daunorubicin 90 mg/m2); >60 y: dauno 60 mg/m2

• Newer regimens if **_unfit_** (generally age ≥75 y or comorbidities; _Leukemia_ 2013;27:997)

venetoclax (Bcl2 inhibitor) + _either_ hypomethylating agents (azacytidine or decitabine) _or_ low-dose cytarabine (_Blood_ 2019;133:7)

Consolidation therapy

• If enters _complete remission_ (CR) = ANC >1000, plts >100, off RBC Rx, <5% BM blasts

• CR does _not_ equal cure

• Favorable risk: high-dose cytarabine (HiDAC); Intermediate/Poor risk: Allo-HSCT

Refractory/relapsed disease

• _Repeating mutation analysis_ key b/c clonal evolution common and may affect Rx

• FLT3-ITD/TKD mutation: gilteritinib or quizartinib (both potent FLT3 inhibitors)

• _IDH1_ mutation: ivosidenib; _IDH2_ mutation: enasidenib (small-molecule inhib of IDH1 or 2)

• Chemo: MEC (mitoxantrone, etoposide, Ara-C); FLAG-Ida (fludarabine, Ara-C, G-CSF, & idarubicin); CLAM (clofarabine, Ara-C, mitoxantrone)

Prognosis

• CR achieved in 70–80% of 病人 <60 y and in 40–50% for 病人 >60 y

• Overall survival variable, depends on prognostic factors: ranges from <10% of older 病人 with poor-risk tumor genetics to >65% for younger 病人 with favorable prognostic factors

Acute promyelocytic leukemia (APL) (_Blood_ 2009;113:1875)

• Rare, ~8% of AML in U.S.; >90% cure rates

• Atypical promyelocytes (large, granular cells; bilobed nuclei) in blood and bone marrow

• Defined by translocation of retinoic acid receptor: **t(15;17); _PML-RARA_** (>95% of cases)

• **Medical emergency** with **DIC** and **bleeding** common

• Remarkable responses to **all-_trans_\-retinoic acid (ATRA)** & **arsenic trioxide (ATO)**, which induce differentiation of leukemic blasts. ∴ early initiation as soon as APL _suspected_

• Non-high-risk APL: ATRA + ATO (induction + 4 cycles consolidation) → CR ~100%; event-free survival 97% and overall survival 99% at 2 y (_NEJM_ 2013;362:111)

• High-risk APL: WBC >10k at diagnosis. No clear consensus. In general, chemo (anthracycline or gemtuzumab ozogamicin) added to ATRA + ATO induction and consolidation.

• Differentiation (ATRA) syndrome: ~25% of 病人; fever, pulm infiltrates, SOB, edema, HoTN, AKI; tx with dexamethasone 10 mg bid, supportive care (eg, diuresis) (_Blood_ 2008;113:775)

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Classification

• Lymphoblastic neoplasms may present as acute leukemia (ALL) with >**20% BM blasts** or as lymphoblastic lymphoma (LBL) with mass lesion with <20% BM blast

• Morphology: **no granules** (granules seen in myeloid lineage)

• Cytochemistry: ⊕ terminal deoxynucleotidyl transferase (TdT) in 95% of ALL

• Immunophenotype

Precursor: CD34, TdT

B: CD19; variable CD10, CD22, CD79a

T: CD1a, CD2, cytoplasmic CD3, CD5, CD7

治療

• **Induction chemo**

Ph ⊕ t(9;22) (seen in ~25% of B-ALL): tyrosine kinase inhibitor + chemo/steroids Adolescents & young adults (<40 y): pedi-like regimen typically with PEG-asparaginase Adults (40–75 y): multiagent chemo incl. anthracycline, vincristine, steroids, CYC Older (>75 y): reduced-intensity chemo

• **CNS prophylaxis:** intrathecal MTX/cytarabine ± cranial irradiation _or_ systemic MTX

• **Postremission therapy** (choice depends on risk of recurrence)

1) Average risk: consolidation/intensification chemo (~7 mo) → maintenance (~2–3 y)

2) High risk: high-dose chemo with allo HSCT considered for 病人 in CR1. High-risk disease includes: Ph ⊕; Ph-like (based on gene expression); MLL translocation t(4;11); complex karyotype; hypodiploid (<44 chromosomes); early T-cell phenotype (ETP; lacks CD1a, CD8, CD5weak, myeloid markers); minimal residual disease (MRD) = morphologic remission but flow cytometry or molec. markers of tumor still detectable.

• **Relapse/refractory:** salvage therapy (_below_), then allogeneic HSCT if able

_B cell:_ blinatumomab (CD19 BiTE-bispecific T-cell engager; _NEJM_ 2017;376:836), inotuzumab (CD22 Ab drug conjugate; _NEJM_ 2016;375:740); tisagenlecleucel (CD19 CAR-T cell, _NEJM_ 2018;378:449), TKI+chemo/steroids (Ph ⊕ t(9;22) only)

_T cell:_ nelarabine

_Both B & T cell:_ chemo including high-dose cytarabine regimens; clofarabine

CHRONIC MYELOGENOUS LEUKEMIA (CML)

定義 (_Blood_ 2009;114:937)

• **Myeloproliferative neoplasm** with clonal overproduction of hematopoietic myeloid stem cells that can differentiate

• **Philadelphia chromosome** (Ph) = t(9;22) → **BCR-ABL** fusion → ↑ Abl kinase activity

_BCR-ABL required for diagnosis_ (make via karyotyping or FISH; PCR)

流行病學 and risk factors

• ~6600 new cases/y in U.S.; median age ~64 at presentation; ~15% of adult leukemias

• ↑ risk with irradiation; no clear relation to cytotoxic drugs

Disease classification & 表現

• **Chronic phase (CP):** <10% blasts (peripheral or bone marrow)

• **Accelerated phase (AP):** 10–19% blasts, ≥20% basos, plts <100k, clonal evolution (karyotype changes) not seen at dx, megakaryocyte proliferation & fibrosis

• **Blastic phase (BP):** ≥20% blasts (2/3 with myeloid, 1/3 with lymphoid), may see extramedullary leukemia

• 85% present in the chronic phase, classic triphasic 臨床course rarely seen in TKI era

• Most 病人 asx or may have mild constitutional signs and symptoms related to splenomegaly.

• Worsening constitutional sx, bone pain, rapid ↑ in spleen size herald disease progression

Diagnostic evaluation

• **Peripheral smear: leukocytosis**, left-shifted with _all stages of myeloid maturation;_ anemia, thrombocytosis, **basophilia**

• **Bone marrow with karyotype:** hypercellular, ↑ myeloid to erythroid ratio

治療 (_Lancet_ 2015;385:1447; _Hematol Oncol Clin North Am_ 2017;31:577)

• **Tyrosine kinase inhibitors (TKI)** inhibit abl kinase activity

First line: imatinib, 1st TKI against BCR-ABL, remains gold standard (_NEJM_ 2017;376:917). 2nd gen TKI: nilotinib, dasatinib, bosutinib; ↑ potency abl inhibitors, but ↑ toxicity.

Resistance: due to ↑ in BCR-ABL transcript level on TKI, often result of _BCR-ABL_ mutation or amplification. Nilotinib, dasatinib, bosutinib & ponatinib approved for resistant disease, with only ponatinib effective on T315I resistance mutation (_NEJM_ 2012;367:2075).

Side effects: nausea, diarrhea, muscle cramps, cytopenias, ↓ PO4, ↑ QT, rarely CHF; dasatinib: pericardial & pleural effusions and pulm HTN; nilotinib: ↑ bili & lipase, CV toxicity; ponatinib: pancreatitis and arterial vascular events (cerebral, cardiac, & PAD)

• TKI discontinuation: consider if complete molecular response (>4.5 log reduction in bcr-abl transcript) for >2 y. Up to 50% of 病人 remain off TKI at 2 y (ie, no molec. recurrence). Likelihood of success proportional to duration of CMR and risk score at presentation.

• Consider upfront allogeneic HSCT for AP and BP.

• CML in pregnancy: hydroxyurea & all TKIs contraindicated. If Rx needed IFN an option.

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Milestones of Therapy</b></p></td></tr><tr><td><p><b>定義</b></p></td><td><p><b>Optimal Time</b></p></td></tr><tr><td><p>BCR-ABL ratio &lt;10% IS = 1-log reduction by quantitative PCR</p></td><td><p>3 mo</p></td></tr><tr><td><p>BCR-ABL ratio &lt;1% IS or &lt;35% Ph chr in metaphase cells</p></td><td><p>6 mo</p></td></tr><tr><td><p>Absence of the Ph chromosome in metaphase cells</p></td><td><p>12 mo</p></td></tr><tr><td><p>BCR-ABL ratio &lt;0.1% IS = 3-log reduction by quantitative PCR</p></td><td><p>12 mo</p></td></tr><tr><td colspan="2"><p>BCR-ABL ratio determined using RT-PCR &amp; compares expression of BCR-ABL fusion in Pt to averaged expression in unRx’d 病人. Reported on International Scale (IS), which standardizes reporting across labs.</p></td></tr></tbody></table>

Prognosis (_NEJM_ 2017;376:917)

• Chronic phase CML Rx’d with imatinib: 89% 5-y overall survival, 95% survival free of CML-related deaths, 7% progression to blast phase at 5 y (_NEJM_ 2006;355:2408). 病人 with 4 log ↓ in bcr-abl transcript have normal life expectancy.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

_see “Small Lymphocytic Lymphoma”_
